Navigation Links
Bradmer announces 2008 first quarter operational and financial results
Date:5/9/2008

the first patients in this trial and are pleased with our accomplishments of building a Phase III company in the last 18 months for less than $17 million dollars. The large expenses in developing the completed manufacturing process and ramping up toward the trial are behind us and we now go into the per patient costings as we execute this trial."

The Phase III trial will investigate Neuradiab as an adjuvant therapy to surgery, external beam radiation and temozolomide in 760 patients with newly diagnosed glioblastoma multiforme (GBM). The randomized trial is expected to be conducted at leading brain tumor treatment centers across the U.S.

Financial Highlights

Amounts in US dollars, unless specified otherwise, and results expressed in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

For the three-month period ended March 31, 2008, we recorded a net loss of $3,157,000, or $0.23 per common share based on the weighted average outstanding shares of 13,488,215. This compares to a net loss of $1,854,000, or $0.24 per common share for the three months ended March 31, 2007 based on the weighted average outstanding shares of 7,781,346. The increased loss in 2008 was primarily related to planned research and development spending with regard to the Company's lead clinical program, Neuradiab, in preparation for the proposed clinical trial, as well as the growth in the Company's administrative functions in anticipation of the clinical trial launch.

Research and development expenses for the first quarter of 2008 were $2,268,000, an increase of $864,000 from $1,404,000 in the same period of 2007. The increase was primarily due to increased costs associated with manufacturing and support for our Phase III clinical development program. The expenses incurred in 2008 were primarily related to amounts paid under drug manufacturing contracts of $1,382,000, as well as amounts paid to clinical and regulatory collaborators
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Bradmer announces new additions to management team
2. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
3. Notice of Bradmer Pharmaceuticals Conference Call
4. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
5. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
6. Bradmer announces additions to Scientific Advisory Board
7. Bradmer Medical Isotope Supply For Phase III Trial Secure
8. Bradmer to present at Rodman & Renshaw Healthcare Conference
9. Bradmer provides Phase III Neuradiab trial update and guidance
10. Bradmer announces management changes
11. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... be given to healthy volunteers in the UK, The ... of an series of safety trials of potential vaccines ... than 1,400 people in the current outbreak in West ... co-developed by the US National Institutes of Health (NIH) ... an international consortium in response to the Ebola epidemic, ...
(Date:8/28/2014)... Catalent Pharma Solutions, the leading global ... for drugs, biologics and consumer health products, today ... Services, and Chris Greco, Manager, Comparator and Ancillary ... Active Control Clinical Trials” at the forthcoming US ... the 9th – 10th September, 2014 in Philadelphia, ...
(Date:8/28/2014)... vaccine to prevent Ebola virus disease will begin next ... Diseases (NIAID), part of the National Institutes of Health. ... of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) ... to generate an immune system response in healthy adults. ... in Bethesda, Maryland. , The study is the first ...
(Date:8/28/2014)... A subset of patients with stage III colon ... therapy, according to a new study in ... the American Gastroenterological Association. , When added to the ... irinotecan therapy improved overall survival rates for patients with ... in about 10 to 20 percent of colorectal cancers. ...
(Date:8/28/2014)... over who identify themselves as ,old, feel worse about ... have lower value than younger age groups. , New ... ,Being old and ill, across different countries: social status, ... from the European Social Survey. Respondents, who were all ... health., The researchers found that those living in societies ...
Breaking Medicine News(10 mins):Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:Drug shows promise for subset of stage III colon cancer patients 2
... ALEXANDRIA, Va., July 23 The model for,person-centered long ... to testimony submitted today to the US Senate Special ... care that embraces choice,independence and the opportunity for seniors ... Richard Grimes, the President and CEO,of the Assisted Living ...
... had heart trouble, the worse their performance , , WEDNESDAY, July ... heart disease seem to fare worse on measures of cognitive ... disease, the worse the performance in such mental processes as ... the July 23 issue of the European Heart Journal ...
... Three years after Hurricane Katrina devastated parts of the Gulf ... Public Health Project on the Public and Biological Security shows ... they are very prepared if a major hurricane were to ... worries of respondents threatened or hit by Hurricane Katrina are ...
... Cohen Hired As New CEO, ATLANTA, July 23 ... MELCO Investments LLC, a private business and,real estate investment ... a,substantial capital investment in GMCG. Along with the investment, ... leading colon and rectal,surgeons, as its new CEO., ...
... and Medicare Rules Highlighted; a Focus on Preventing ... Hospital-acquired Conditions, LANSING, ... a national leader in clinical risk management,practice and patient safety programs ... for its annual risk,management conference., The conference will take place ...
... the #1 Healthiest City to,Live and Retire In -, ... voice for 50+ Americans and the world,s largest-circulation,magazine with ... ten,healthiest cities to live and retire in with Ann ... Fargo, ND taking the top five rankings.,Featured in the ...
Cached Medicine News:Health News:ASSISTED LIVING: The Model for Person-Centered Long Term Care 2Health News:Coronary Disease Dulls Cognitive Skills 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 3Health News:Hurricane preparedness survey: Worries about drinking water and medical care 4Health News:Hurricane preparedness survey: Worries about drinking water and medical care 5Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5
(Date:8/28/2014)... , Aug. 28, 2014 The Leukemia ... a partnership to advance an experimental cancer vaccine ... an asymptomatic stage of myeloma. The ... through which LLS forges collaborations with biotechnology companies ... OncoPep is developing a vaccine, PVX-410, ...
(Date:8/28/2014)... ANTONIO , Aug. 28, 2014 GenSpera, ... for the treatment of cancer, announces the recent publication ... journal Steroids . The recent article ... reviews the evolution and development of GenSpera,s prodrug technology platform ... of thapsigargin (from the plant Thapsia garganica ) ...
(Date:8/28/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) a leading ... for the eye, today announced that management will present at ... Palace Hotel on Wednesday, September 3 at 7:15 a.m. PT/10:15 ... CEO will offer a general overview of the Company,s current ... by Steve Brown , CFO, and Sam Gesten ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society Provides Equity Financing to OncoPep to Support Clinical Trial for Myeloma Vaccine 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3STAAR Surgical To Present At The Baird 2014 Health Care Conference 2
... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... of the largest network of radiotherapy and diagnostic imaging ... directors approved a share repurchase program, effective immediately. ... States federal securities laws, Concord Medical is authorized to ...
... Sept. 29, 2011 The Educational Review System held ... 28 at the Meyedenbauer Center in Bellevue, WA. Attendees ... pharmacy thought leaders discuss the challenges of pediatric medications, ... the 2010 recipient of the Institute for Safe Medication ...
Cached Medicine Technology:Concord Medical Services Announces Share Repurchase Program 2Concord Medical Services Announces Share Repurchase Program 3
6 mm, 45 degree upwards, detachable....
Aaron 950 is a high frequency desiccator with cut....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: